This article was adapted from STAT’s latest report, “Subgroup analysis: how to evaluate post hoc tests for significance in failed clinical trials.”
Clinical trials of newly developed drugs often don’t work out.
When that happens, it’s common practice for biotech and pharma companies to look for ways to salvage their financial investment, often conducting further data analyses in particular types of patients after the fact, to see if the compound might have been effective in those smaller groups.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect